#HEMEPATH

Dr. Sanam Loghavi, MD, Associate Professor, Department of Hematopathology, MD Anderson Cancer Center, USA, discusses "Navigating Change and Integrating WHO 5th/ ICC Classification Systems in the diagnosis of AML and MDS"
Follow #pathCast on:
KZbin: / @pathcast
X : / pathologycast
Instagram: / pathcast2016
Website: pathologycast.com/index.php/p...

[@simazolfaghari5963]

Thank you!

[@justsmilejustsmile3155]

Thank you❤

[@Torecan]

In minute 26, refering to AML defining genetic abnormalities classification I don't think is that clear that WHO establishes distinction regarding the number of blast requirement (increased vs no minimum threshold). I've checked the WHO 5th classification online resource and it says for NPM1 "Essential (diagnostic criteria): a myeloid neoplasm with increased peripheral blood and/or bone marrow blasts (may be < 20%)" which is just the same comment than for RUNX1... However I'm sure dr Loghavi had good reasons to make that comment

[@larkinwalker6659]

Thank you!